Investor Presentaiton
23
Investor presentation Full year 2022
Sales growth of 16%, driven by the GLP-1 portfolio for diabetes
and obesity treatment
Novo Nordisk reported quarterly sales
DKK
billion
by therapy
Reported sales for the full
year 2022
Reported sales and growth breakdown for
the full year 2022
Novo NordiskⓇ
50
Rare
Other
Therapy
Reported sales
CAGR1: 9.2%
Sales
(mDKK)
Growth
Share of
growth
40
40
Rare endocrine rare
blood disorders disease
Total GLP-12
83,371
42%
98%
Long-acting insulin³
16,741
-13%
-10%
disorders
1%
Premix insulin+
10,562
-10%
-5%
-5.1%1
4%
7%
Fast-acting insulin
17,463
-7%
-5%
30
Obesity
Human insulin
0.4%¹
8,186
-16%
-6%
care
9%
Total insulin
52,952
-11%
-26%
3.6%1
Other Diabetes care
3,225
-15%
-2%
20
10.6 %1
Total Diabetes care
139,548
14%
69%
Obesity care?
16,864
84%
30%
10
79%
Diabetes and Obesity care
156,412
19%
99%
Diabetes care
Rare blood disorders
11,706
7%
3%
0
Q4
Other rare disease
2012
Rare endocrine disorders
Rare blood disorders
Q4
2022
Rare endocrine disorders⁹
Other Rare disease 10
Rare disease
7,138
-6%
-2%
1,698
-3%
0%
20,542
1%
1%
Diabetes and Obesity care
Sales of DKK 177.0 billion
(+26%)
Total
176,954
16%
100%
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and Novo MixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ: 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and Wegovy®: 8 Comprises NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ: 9 Comprises Norditropin and Macrilen TM; 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 26%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation